Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 462 participants.
Also called NCT01301833
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 462 participants
- Sponsor
- Registry
-
NCT01301833
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01301833. Non-randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-08-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- teneligliptin
- Intervention (Drug)
- glinide
- Intervention (Drug)
- biguanide
- Intervention (Drug)
- alpha-glucosidase inhibitor
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct01301833- Content hash
0d739827f35b16d2b34f49b3ca22b24b359c9a85864201b3d4f5a2b80630bb51